tiprankstipranks
Trending News
More News >
AcouSort AB (SE:ACOU)
:ACOU

AcouSort AB (ACOU) AI Stock Analysis

Compare
0 Followers

Top Page

SE:ACOU

AcouSort AB

(ACOU)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 5.2)
Rating:46Neutral
Price Target:
kr2.50
▼(-5.30% Downside)
The score is held down primarily by persistent losses and significant negative cash flow despite strong recent revenue growth, which increases financing/dilution risk. Technicals add only modest support with short-term strength but a longer-term downtrend and negative MACD. Valuation is also constrained by a negative P/E and no stated dividend yield.
Positive Factors
Revenue Growth
The strong revenue growth indicates increasing demand for AcouSort's products, suggesting potential for market expansion and improved financial performance over time.
Debt-Free Balance Sheet
A debt-free balance sheet enhances financial stability and flexibility, allowing the company to invest in growth opportunities without the burden of interest payments.
Innovative Technology
AcouSort's innovative acoustofluidic technology positions it well in the growing biotech sector, offering competitive advantages in cell therapy and bioprocessing markets.
Negative Factors
Weak Profitability
Persistent weak profitability and large operating losses indicate challenges in achieving a sustainable business model, potentially limiting long-term growth.
Negative Cash Flow
Negative cash flow highlights ongoing cash burn, increasing the risk of funding dependence and potential dilution if the company cannot achieve profitability.
Volatile Revenue
Volatile revenue patterns suggest instability in the business model, making it challenging to predict future performance and achieve consistent growth.

AcouSort AB (ACOU) vs. iShares MSCI Sweden ETF (EWD)

AcouSort AB Business Overview & Revenue Model

Company DescriptionAcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.
How the Company Makes MoneyAcouSort AB generates revenue through the sale of its acoustic separation systems and devices to research institutions, diagnostic companies, and clinical laboratories. The company also earns income by providing custom solutions and services that leverage its proprietary technology for specific customer needs. Additionally, AcouSort may engage in partnerships and collaborations with other companies and research entities to further develop and market its technologies, which can also contribute to its revenue streams through licensing agreements or joint ventures. The company's earnings are influenced by the demand for advanced diagnostic and research tools that can offer improved efficiency and accuracy in biological sample processing.

AcouSort AB Financial Statement Overview

Summary
AcouSort AB faces financial challenges with declining revenues, consistent net losses, and negative cash flow, which could affect its long-term viability. While the lack of debt is a positive, the company's operational and profitability struggles need to be addressed.
Income Statement
24
Negative
The company shows a volatile revenue trajectory with a significant drop in revenue from 2023 to 2024. Gross profit margin has been inconsistent, and the company is operating at a net loss, indicating profitability challenges. The negative EBIT and EBITDA margins highlight operational inefficiencies.
Balance Sheet
62
Positive
The equity ratio is stable, suggesting a solid capital structure with no debt, which reduces financial risk. However, the declining stockholders' equity over time and persistent net losses could pose future financial stability risks.
Cash Flow
18
Very Negative
The company experiences negative free cash flow, indicating potential cash management challenges. The operating cash flow is consistently negative, suggesting difficulties in covering operating expenses through core business activities.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.62M4.74M10.55M4.96M3.01M4.93M
Gross Profit880.00K4.77M8.39M2.91M548.00K3.04M
EBITDA-11.98M-15.89M-16.70M-12.86M-11.46M-7.64M
Net Income-12.36M-15.08M-17.09M-13.21M-12.38M-8.22M
Balance Sheet
Total Assets21.86M12.32M34.51M42.66M36.56M13.17M
Cash, Cash Equivalents and Short-Term Investments11.83M3.57M23.99M33.97M31.52M8.12M
Total Debt0.000.000.000.000.000.00
Total Liabilities3.21M3.86M10.38M22.54M3.54M3.58M
Stockholders Equity18.65M8.46M24.14M20.11M33.02M9.59M
Cash Flow
Free Cash Flow-16.96M-19.84M-31.77M2.95M-12.23M-8.63M
Operating Cash Flow-16.42M-18.81M-31.56M3.96M-10.92M-7.04M
Investing Cash Flow503.00K-1.02M-1.16M-1.01M-1.31M-1.59M
Financing Cash Flow18.87M-157.00K22.08M0.0035.63M11.65M

AcouSort AB Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.64
Price Trends
50DMA
2.73
Positive
100DMA
2.94
Negative
200DMA
3.20
Negative
Market Momentum
MACD
0.09
Negative
RSI
52.70
Neutral
STOCH
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Neutral. The current price of 2.64 is below the 20-day moving average (MA) of 2.69, below the 50-day MA of 2.73, and below the 200-day MA of 3.20, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 52.70 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACOU.

AcouSort AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
kr75.12M-9.16-78.79%20.55%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
kr159.86M-5.11-264.12%-17.80%-11.96%
46
Neutral
kr60.95M-3.94-80.90%59.70%44.60%
46
Neutral
kr55.99M-0.86-88.65%8.46%11.73%
44
Neutral
kr76.85M-5.45-601.02%
43
Neutral
kr44.55M-1.018.47%-94.12%-25.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ACOU
AcouSort AB
2.86
-7.39
-72.10%
SE:PILA
PILA PHARMA AB
2.10
-1.70
-44.72%
SE:ONCOZ
OncoZenge AB
5.81
-0.88
-13.15%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
15.78
-8.02
-33.70%
SE:LARK
CombiGene AB
2.28
0.04
1.60%
SE:SPRINT
Sprint Bioscience AB
1.54
-0.04
-2.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 30, 2025